US5593673A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Isolated porcine pancreatic cells for use in treatment of diseases characterized by insufficient insulin activity
Assignee: Genvec Inc
•
Filing: 1995-05-12
•
Granted: 1997-01-14
•
Expires: 2015-05-12
Abstract
Abstract Isolated porcine pancreatic cells, isolated populations of such cells and methods for isolating and using the cells to treat subjects with diseases characterized by insufficient insulin activity are described. The porcine pancreatic cells are preferably non-insulin-secreting porcine pancreatic cell having the ability to differentiate into an insulin-secreting cell upon introduction into a xenogeneic subject, such as a human subject. Such cells include embryonic porcine pancreatic cells obtained from embryonic pigs between about day 31 and day 35 of gestation. The porcine pancreatic cells can be modified to be suitable for transplantation into a xenogeneic subject, for example, by altering an antigen (e.g., an MHC class I antigen) on the cell surface which is capable of stimulating an immune response against the cell in the subject (e.g., by contact with an anti-MHC class I antibody, or a fragment or derivative thereof). The isolated porcine pancreatic cells of the invention can be used to treat diseases characterized by insufficient insulin activity, e.g., Type I and Type II diabetes, by administering the cells to a subject having such a disease.
Inventors
- 👤 Jonathan Dinsmore
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-30 16:49
CPC Classifications
C; C12; C12N; C12N5/00; C12N5/06; C12N5/0602; C12N5/0676; C12N5/0678; A; A61; A61K; A61K35/00; A61K35/12; A61K35/37; A61K35/39; A61K39/00; A61K39/35
Claims Analysis
Total Claims: 26
Claim 1
Independent Claim
21 words
An isolated non-insulin-secreting porcine pancreatic cell having the ability to differentiate into an insulin-secreting cell upon introduction into a xenogeneic subject.
Claim 2
Dependent Claim
21 words
An isolated non-insulin-secreting porcine pancreatic cell having the ability to differentiate into an insulin-secreting cell upon introduction into a xenogeneic subject.
Claim 3
Dependent Claim
20 words
The isolated cell of claim 1, further having the ability to produce glucagon prior to introduction into the xenogeneic subject.
Claim 4
Dependent Claim
20 words
The isolated cell of claim 1, further having the ability to produce somatostatin prior to introduction into the xenogeneic subject.
Claim 5
Dependent Claim
13 words
The isolated cell of claim 1, which is obtained from an embryonic pig.
Claim 6
Dependent Claim
23 words
The isolated cell of claim 4, which is obtained from an embryonic pig between about day 31 and about day 35 of gestation.
Claim 7
Dependent Claim
22 words
An isolated population of non-insulin-secreting porcine pancreatic cells having the ability to differentiate into insulin-secreting cells upon introduction into a xenogeneic subject.
Claim 8
Dependent Claim
22 words
An isolated population of non-insulin-secreting porcine pancreatic cells having the ability to differentiate into insulin-secreting cells upon introduction into a xenogeneic subject.
Claim 9
Dependent Claim
15 words
The isolated population of cells of claim 6, which is obtained from an embryonic pig.
Claim 10
Dependent Claim
25 words
The isolated population of cells of claim 7, which is obtained from an embryonic pig between about day 31 and about day 35 of gestation.
Claim 11
Dependent Claim
60 words
The isolated population of cells of claim 6, wherein the cells, in unmodified form, have at least one antigen on the cell surface which is capable of stimulating an immune response against the cells in a xenogeneic subject, wherein the antigen on the surface of the cells is altered to inhibit rejection of the cells when administered to the subject.
Claim 12
Dependent Claim
24 words
The isolated population of cells of claim 9, wherein the antigen on the cell surface which is altered is an MHC class I antigen.
Claim 13
Dependent Claim
54 words
The isolated population of cells of claim 10, which is contacted prior to introduction into a xenogeneic subject with at least one MHC class I antibody, or fragment or derivative thereof, which binds to the MHC class I antigen on the cell surface but does not activate complement or induce lysis of the cell.
Claim 14
Dependent Claim
22 words
The isolated population of cells of claim 11, wherein the MHC class I antibody is an anti-MHC class I F(ab') 2 fragment.
Claim 15
Dependent Claim
26 words
The isolated population of cells of claim 12, wherein the MHC class I F(ab') 2 fragment is a F(ab') 2 fragment of a monoclonal antibody PT85.
Claim 16
Dependent Claim
14 words
A delivery device having a needle, the device containing the cells of claim 6.
Claim 17
Dependent Claim
10 words
The delivery device of claim 14 which is a syringe.
Claim 18
Dependent Claim
36 words
A cell culture comprising a population of non-insulin-secreting porcine pancreatic cells having the ability to differentiate into insulin-secreting cells upon introduction into a xenogeneic subject and a medium suitable to support the growth of the cells.
Claim 19
Dependent Claim
36 words
A cell culture comprising a population of non-insulin-secreting porcine pancreatic cells having the ability to differentiate into insulin-secreting cells upon introduction into a xenogeneic subject and a medium suitable to support the growth of the cells.
Claim 20
Dependent Claim
27 words
A method of treating a disease characterized by insufficient insulin activity in a subject, comprising administering to a subject having the disease the cells of claim 6.
Claim 21
Dependent Claim
14 words
The method of claim 17, wherein the cells are obtained from an embryonic pig.
Claim 22
Dependent Claim
24 words
The method of claim 18, wherein the cells are obtained from an embryonic pig between about day 31 and about day 35 of gestation.
Claim 23
Dependent Claim
11 words
The method of claim 17, wherein the subject is a human.
Claim 24
Dependent Claim
12 words
The method of claim 20, wherein the disease is Type II diabetes.
Claim 25
Dependent Claim
14 words
The method of claim 17, further comprising administering an immunosuppressive agent to the subject.
Claim 26
Dependent Claim
27 words
A method of treating a disease characterized by insufficient insulin activity in a subject, comprising administering to a subject having the disease the cells of claim 9.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2000-01-14 | 2000-07-15 | 2001-01-14 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2004-01-14 | 2004-07-15 | 2005-01-14 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2008-01-14 | 2008-07-15 | 2009-01-14 | $7700.00 | Window Closed / Lapsed |